COMMUNIQUÉS West-GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2019
02/08/2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France LYON, France, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – 31 Juillet 2019
02/08/2019
Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Lyon - France LYON, France, 02 août 2019 (GLOBE NEWSWIRE) -- Places de cotation : Euronext Paris de Euronext (Compartiment C - Code ISIN : [...]
Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2019
02/08/2019
Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2019 LYON, France, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – 31 Juillet 2019
02/08/2019
Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers LYON, France, 02 août 2019 (GLOBE NEWSWIRE) -- Places de cotation : Euronext Paris de Euronext (Compartiment C - Code ISIN : FR0011471135 – [...]
AB Science today reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma
02/08/2019
Paris, August 2, 2019, 5.30pm AB Science announces new clinical results in oncology: Masitinib showed activity in metastatic melanoma bearing the juxta-membrane mutation of c-Kit AB Science SA (NYSE Euronext - [...]
AB Science annonce aujourd’hui les résultats de son étude de phase 3 évaluant le masitinib chez des patients atteints de mélanome non opérable ou métastatique de stade 3 ou stade 4
02/08/2019
Paris, 2 août 2019, 17h30 AB Science annonce de nouveaux résultats cliniques en oncologie : L’activité du masitinib a été démontrée dans le mélanome métastatique présentant une mutation du domaine juxta-membranaire de c [...]
Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs
02/08/2019
Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) announced today that it intends to delist its American Depositary Shares (“ADS”) from the Nasdaq Capital Market (“NASDAQ”) and to deregister and terminate its [...]
Ecomed Solutions Receives Innovative Technology Contract from Vizient for Its Novel Blood Management Device, HEMAsavR™
02/08/2019
MUNDELEIN, Ill., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Ecomed Solutions , the developer and manufacturer of innovative healthcare solutions, announced its HEMAsavR ™ has received an Innovative Technology contract from [...]
BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to Nasdaq
02/08/2019
SAN CARLOS, Calif., Aug. 02, 2019 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NasdaqCM: BCDA, BCDAW), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the [...]
Wildflower Brands Closes on Private Placement
02/08/2019
VANCOUVER, British Columbia,, Aug. 02, 2019 (GLOBE NEWSWIRE) -- via NetworkWire: Wildflower Brands Inc. (CSE: SUN) (the “Company”) wishes to announce it has received subscriptions for a convertible debenture financing [...]
Predictive Laboratories to Present New Endometriosis Discoveries in Three Presentations at Leading Scientific Conference Focused on Human Infertility
02/08/2019
American Society of Reproductive Medicine selects findings through scientific peer-review process for presentations at the 75th ASRM Scientific Congress & Expo in October SALT LAKE CITY, Aug. 02, 2019 (GLOBE [...]
Autolus Therapeutics to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8
02/08/2019
LONDON, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release [...]
Agile Therapeutics Announces Pricing of $12 Million Underwritten Public Offering of Common Stock
02/08/2019
PRINCETON, N.J., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 12,631,579 shares of its [...]
Alphatec to Present at the Canaccord Genuity 39th Annual Growth Conference
02/08/2019
CARLSBAD, Calif., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine [...]
Shineco, Inc. Announces Strategic Cooperation Agreement for Acquisition to Construct China’s First Industrial Hemp Museum
02/08/2019
BEIJING, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, specialized textiles, and [...]
Unum Therapeutics to Review Second Quarter 2019 Financial Results on August 12, 2019
02/08/2019
CAMBRIDGE, Mass., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing potentially curative cellular immunotherapies through its ACTR and BOXR [...]
OrthoPediatrics Corp. to Report Second Quarter 2019 Financial Results on August 7, 2019
02/08/2019
Conference Call to Discuss Results on August 8, 2019 at 8:00 a.m. ET WARSAW, Ind., Aug. 02, 2019 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ:KIDS), a company focused exclusively on advancing [...]
Obalon Therapeutics Inc. Announces Pricing of $15,000,000 Public Offering
02/08/2019
SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (Nasdaq: OBLN) (the “Company”) , a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled [...]
GBT Announces New Employment Inducement Grants
02/08/2019
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2019, the compensation committee of GBT’s board of directors granted [...]

Pages